Compare Abeona Therapeutics Inc (ABEO) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs MINISO Group Holding Ltd — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while MINISO Group Holding Ltd trades at $12.02 (market cap $3.74B). The key difference: MINISO Group Holding Ltd is far larger — about 8.8× Abeona Therapeutics Inc's market cap, and MINISO Group Holding Ltd pays a 5.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MNSO | |
|---|---|---|
Market Cap | $424.33M | $3.74B |
Sector | Health | Technology |
52-Week High | $7.45 | $26.63 |
52-Week Low | $4.17 | $11.30 |
Enterprise Value | $279.23M | $4.41B |
Dividend Yield | — | 5.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
MNSO trades at $12.55, showing minimal daily movement (-0.08%). The stock exhibits neutral technical signals with bearish moving averages, trading near key support at $12. Fundamentally, the company reported strong Q1 2026 earnings that beat expectations with 28.5% revenue growth, though recent quarters showed mixed results. The company announced a HK$2 billion share repurchase program in June 2026, signaling management confidence in undervalued shares.
MNSO presents a compelling value opportunity with attractive valuation ratios (P/E 12.65, P/S 1.15) and improving profitability (2026 net margin projected at 8.98%). However, investors face risks from margin compression and volatile quarterly performance. With 75% analyst buy ratings and technical support at current levels, the stock offers upside potential but requires monitoring of execution consistency and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
